Ophthalmology Drug Development Pipeline Review, 2016

Hexa Reports
Market Research Reports and Insightful Company Profiles
2016 Ophthalmology Pipeline Review: Analysis of
Companies Involved in Therapeutics Development
Ophthalmology Drug Development Pipeline Review, 2016 report provides comprehensive information on
the pipeline development landscape for glaucoma, age-related macular degeneration, diabetic
retinopathy, diabetic macular edema and keratoconjunctivitis sicca (dry eye), from Discovery through to
the Pre-Registration stage. This includes an analysis of products by stage of development, molecular
target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products
in development is provided, including dormant and discontinued projects. Finally, the report provides an
overview of key players involved in the development of products in this area, and outlines recent updates
and press releases in the field.
Browse Detail Ophthalmology Drug Development Pipeline Review Market Research Report @
http://www.hexareports.com/report/ophthalmology-drug-development-pipeline-review2016/details
Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious longterm co-morbidities such as diabetes, and particularly blindness, can arise. Although there are a number
of treatments approved in ophthalmology, there are currently no curative therapies for any of these
indications. In particular, there are strong unmet needs within age-related macular degeneration and
glaucoma, which can lead to blindness if not adequately treated.
Hexa Reports
Market Research Reports and Insightful Company Profiles
Although there is a high degree of failure and uncertainty within the R&D of pharmaceuticals, there is a
great deal of interest in ophthalmology development. Overall, there are over 700 products in active
development in the ophthalmology therapy area, making it one of the largest therapy area pipelines.
Although two thirds of products in development for ophthalmology disorders are at the Discovery or
Preclinical stage of development, the number of drugs in the pipeline is very high, creating strong potential
for a blockbuster drug to enter the market.
Get Sample PDF of Report @ http://www.hexareports.com/sample/169580
2016 Ophthalmology Drug Development Pipeline Review Helps to Answer Following Questions:
 Which companies are the most active within the pipeline for ophthalmology?
 Which pharmaceutical approaches are the most prominent at each stage of the pipeline and
within each indication?
 To what extent do universities and institutions play a role within this pipeline, compared to
pharmaceutical companies?
 What are the most important R&D milestones and data publications to have occurred in
ophthalmology?
Reasons To Buy
1. Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic
development for each indication.
2. Assess the products in development in granular detail, with an up-to-date overview of each
individual pipeline program in each indication, and a comprehensive picture of recent updates
and milestones for each.
3. Analyze the companies, institutions and universities currently operating in the pipeline, and the
products being fielded by each of these.
4. Understand the composition of the pipeline in terms of molecule type, molecular target,
mechanism of action and route of administration.
Detail TOC of Ophthalmology Drug Development Pipeline Review:
 Introduction
 Therapeutics Development by Stage
 Therapeutics under Development by Companies
 Therapeutics under Investigation by Universities/Institutes
 Pipeline Products Glance
 Products under Development by Companies
 Products under Investigation by Universities/Institutes
 Companies Involved in Therapeutics Development
 Therapeutics Assessment
 Dormant Projects
 Discontinued Products
Hexa Reports
Market Research Reports and Insightful Company Profiles


Product Development Milestones
Appendix
Explore Latest Market Research Reports:
Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence
and Launch of Targeted Therapies: http://www.hexareports.com/report/gastric-cancer-therapeuticsin-asia-pacific-markets-to-2022
Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence,
Growing Awareness and Expected Launch of Anabolic Therapies:
http://www.hexareports.com/report/osteoporosis-therapeutics-in-asia-pacific-markets-to-2022
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/
Visit our Blog: http://hexareports.blogspot.com/
Like our Facebook page: https://www.facebook.com/hexareportsindustry/
Follow us on LinkedIn: https://www.linkedin.com/company/hexa-reports-inc-

Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise